Septerna (NASDAQ:SEPN) Stock Price Expected to Rise, Truist Financial Analyst Says

Septerna (NASDAQ:SEPN) had its price target raised by Truist Financial from $34.00 to $35.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s target price points to a potential upside of 32.38% from the stock’s previous close.

Other research analysts have also issued reports about the company. Raymond James Financial initiated coverage on Septerna in a research note on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price objective for the company. Wells Fargo & Company upped their target price on shares of Septerna from $28.00 to $48.00 and gave the stock an “overweight” rating in a report on Tuesday, March 3rd. HC Wainwright increased their target price on shares of Septerna from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $60.00 price target on shares of Septerna in a report on Tuesday. Finally, Zacks Research upgraded shares of Septerna from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $44.00.

Septerna Trading Up 0.5%

SEPN stock opened at $26.44 on Wednesday. Septerna has a 1-year low of $4.66 and a 1-year high of $32.63. The business’s 50 day moving average is $26.83 and its 200-day moving average is $23.30. The firm has a market cap of $1.19 billion, a P/E ratio of -23.82 and a beta of 3.46.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, March 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The company had revenue of $24.12 million for the quarter, compared to the consensus estimate of $20.44 million. Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%. Sell-side analysts forecast that Septerna will post -7.11 EPS for the current year.

Insider Buying and Selling at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total transaction of $115,880.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $5,046,834.73. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Samira Shaikhly sold 70,453 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the sale, the insider owned 793 shares of the company’s stock, valued at approximately $22,283.30. This trade represents a 98.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Septerna

Several hedge funds have recently modified their holdings of SEPN. Deutsche Bank AG increased its holdings in shares of Septerna by 5.3% in the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after purchasing an additional 744 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Septerna during the 4th quarter worth $35,000. Covestor Ltd boosted its position in Septerna by 55.8% in the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after buying an additional 1,296 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after buying an additional 1,315 shares during the period. Finally, PharVision Advisers LLC increased its stake in shares of Septerna by 17.5% in the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after buying an additional 1,780 shares during the period.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.